Invicta Diagnostic
Invicta Diagnostic (INVICTA) share price was ₹65.00 at the 28 Oct 2026 close; market capitalisation ₹81.72 Cr; sector Healthcare Services. In the Mar 2026 quarter, revenue was ₹15.41 Cr and net profit was ₹0.79 Cr. Promoters held 66.70% of Invicta Diagnostic in Sep 2026, unchanged from Mar 2026. Its Tapetide Score is 43/100 (Weak) as of 28 Oct 2026.
Key Fundamentals
SMEHealthcare ServicesHealthcarePrice-based figures as of 29 Oct 2026, 10:28 IST · TTM
Peer Comparison
Healthcare › Healthcare Services › Healthcare Service Provider
| ₹1,904.90 | 58.90 | 31,974 Cr | 12.75 | 0.26% | 20.06% | 25.67% | 2,996 Cr | 545 Cr | |
| ₹1,439.70 | 78.97 | 14,829 Cr | 15.49 | 0.14% | 18.07% | 19.22% | 879 Cr | 187 Cr | |
| ₹548.50 | 56.37 | 11,375 Cr | 7.57 | 0.91% | 12.54% | 15.73% | 1,733 Cr | 203 Cr | |
| ₹516.65 | 46.63 | 8,223 Cr | 16.04 | 2.84% | 27.79% | 33.84% | 894 Cr | 176 Cr | |
| ₹630.35 | 150.44 | 6,339 Cr | 5.68 | 0.00% | 6.88% | 13.46% | 1,079 Cr | 85 Cr | |
| ₹319.10 | 46.38 | 1,662 Cr | 6.79 | 0.16% | 12.90% | 14.70% | 329 Cr | 35 Cr | |
| ₹494.80 | 16.23 | 1,605 Cr | 1.64 | 0.40% | 10.35% | 10.64% | 862 Cr | 98 Cr | |
| Invicta Diagnostic (this company) | ₹65.00 | — | 82 Cr | 1.64 | 0.00% | 9.76% | 13.57% | — | — |
| Median 8 companies | ₹532.58 | 56.37 | 7,281 Cr | 7.18 | 0.21% | 12.72% | 15.22% | 894 Cr | 176 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 81/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
1- Though the company is reporting repeated profits, it is not paying out dividend
Technical Indicators
Oscillators
Bearish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 19.4% · Mar 2026
Quarterly Results
| Particulars | Sep 2025 | Mar 2026 |
|---|---|---|
| Sales | 16.95 | 15.41 |
| Expenses | 10.19 | 12.42 |
| Operating Profit | 6.76 | 2.99 |
| OPM % | 39.88% | 19.4% |
| Other Income | 0.13 | 0.56 |
| Interest | 0.1 | 0.09 |
| Depreciation | 1.37 | 1.88 |
| PBT | 5.42 | 1.58 |
| Tax % | 24.72% | 50% |
| Net Profit | 4.08 | 0.79 |
| EPS (₹) | 4.32 | 0.72 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 7.46 | 7.99 | 30.1 | 32.35 |
| Expenses | 4.22 | 4.59 | 20.91 | 22.58 |
| Operating Profit | 3.24 | 3.4 | 9.19 | 9.77 |
| OPM % | 43.43% | 42.55% | 30.53% | 30.2% |
| Other Income | 0 | 0.35 | 0.09 | 0.69 |
| Interest | 0.02 | 0.08 | 0.23 | 0.2 |
| Depreciation | 0.95 | 0.98 | 2.49 | 3.25 |
| PBT | 2.27 | 2.69 | 6.56 | 7.01 |
| Tax % | 22.91% | 0% | 25% | 30.39% |
| Net Profit | 1.76 | 2.69 | 4.93 | 4.88 |
| EPS (₹) | — | 3.2 | 5.81 | 3.91 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | — | 0.13 | 8.42 | 12.57 |
| Reserves | — | 12.05 | 5.18 | 37.35 |
| Borrowings | — | 1.87 | 3.53 | 3.67 |
| Other Liabilities | — | 1.79 | 4.09 | 6.65 |
| Total Liabilities | — | 15.84 | 21.22 | 60.24 |
| Fixed Assets | — | 11.78 | 9.58 | 19.2 |
| CWIP | — | 0 | 0 | 0 |
| Investments | — | 0 | 4.33 | 6.2 |
| Other Assets | — | 4.06 | 7.31 | 34.84 |
| Total Assets | — | 15.84 | 21.22 | 60.24 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | — | 4.21 | 6.56 | 2.93 |
| Investing | — | -10.01 | -5.23 | -13.67 |
| Financing | — | 7.14 | -0.5 | 30.79 |
| Net Cash Flow | — | 1.34 | 0.83 | 20.05 |
| Free Cash Flow | — | -8.56 | 6.23 | -9.93 |
| CFO/EBITDA | — | 124 | 71 | 40 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | — | 37.46 | 17.7 | 6.43 |
| Inventory Days | — | 297 | 83.33 | 78.88 |
| Days Payable | — | 1,103 | 70 | 254 |
| Cash Conversion Cycle | — | -769 | 31.04 | -169 |
| Working Capital Days | — | 5.94 | 18.55 | 55.74 |
| ROCE % | — | — | 45.04% | 19.43% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Invicta Diagnostic insights
58 extracted metrics + investor summaries across FY23–FY26.
Documents
Frequently Asked Questions about Invicta Diagnostic
What does Invicta Diagnostic Ltd do?
Where is Invicta Diagnostic Ltd (INVICTA) listed?
Which sector does Invicta Diagnostic Ltd belong to?
What is the market capitalisation of Invicta Diagnostic Ltd?
What is the 52-week high and low of Invicta Diagnostic Ltd?
What is the Return on Equity (ROE) of Invicta Diagnostic Ltd?
Company Information
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions [1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INVICTA.md for Invicta Diagnostic Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.